Search Results 241-250 of 22996 for Phase

1. Phase III Study Of Rilvegostomig In Combination With Bevacizumab With Or Without Tremelimumab As First-line Treatment Of Hepatocellular Carcinoma - Mayo Clinic

   About this study. This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of ...

2. A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea - Mayo Clinic

   A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), ...

3. Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) - Mayo Clinic

   Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) · Share ...

4. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease - Mayo Clinic

   The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by ...

5. A Phase 2/3 Study To Investigate The Safety And Efficacy Of Brepocitinib In Adults With Lichen Planopilaris (ALPINE) - Mayo Clinic

   The purpose of this study is to determine the safety and efficacy of brepocitinib (a tyrosine kinase [TYK]2/Janus kinase [JAK]1 inhibitor) in adult participants ...

6. Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations - Mayo Clinic

   About this study. To determine the antitumor activity of tipifarnib in patients with locally advanced unresectable or metastatic, relapsed and/or refractory ...

7. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

   Clinical Trials · A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with ...

8. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC).

9. A Phase I Study of TAS-102 in Patients with Advanced Solid Tumors with Hepatic Impairment - Mayo Clinic

   Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.

10. Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

    This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for ...